NasdaqGS:TEMLife Sciences
Does Tempus AI’s (TEM) xH Launch Quietly Redraw Its Long‑Term Data Moat Strategy?
Tempus AI recently announced a research collaboration with Angiosarcoma Awareness, Inc. and the clinical availability of its xH whole‑genome sequencing test for hematologic cancers, leveraging one of the largest known angiosarcoma molecular datasets and consolidating multiple diagnostics into a single workflow.
Together, these moves highlight how Tempus AI is using its data assets and AI-enabled assays to deepen rare cancer insights while expanding its clinical and biopharma use cases.
We’ll...